Serum Proteomics of Ribociclib-Mediated Cardiovascular Toxicity: An Exploratory Case-Control Study
Preprint 2025 en
Authors
OF
Oraianthi Fiste
MS
Martina Samiotaki
EM
Efstathios Manios
Abstract
1 min read
Cyclin-dependent kinase 4/6 inhibitors have transformed hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer therapeutics. Ribociclib has been associated with survival gain, yet its potentia
Discussion(0)
No comments yet. Be the first to comment.